Antimicrobial proteins from the SPO1 bacteriophage

Details Antimicrobial proteins from the SPO1 bacteriophage Antimicrobial proteins from the SPO1 bacteriophage

2007-01-02

2007-01-02

Carlson, Karen Cochrane (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

10809761

ABSTRACT:
Anti-bacterial peptides are provided which are derived from the bacteriophage SPO1.

REFERENCES:
patent: 2001/0026795 (2001-10-01), Merril et al.
patent: 2001/0043924 (2001-11-01), Carlton et al.
Sampath et al., “Roles of Specific Genes in Host-Takeover ofB. subtilisby Bacteriophage”, Abstracts of the General Meeting of the American Society for Microbiology. 2002. v.102, p. 302.
Wie. Ph.D. Thesis: A host-shutoff early gene ofBacillus subtilisbacteriophage SPO1. Rice University. 1994.
Sampath et al., “Roles of Specific Genes in Host-Takeover ofB. subtilisby Bacteriophage”, Abstracts of the General Meeting of the American Society for Microbiology. 2002. v.102, p. 302.
Weiss et al. In Vivo Activity of Peptidic Prodrugs of Novel Aminomethyl Tetrahydrofuranyl-1 beta-Methylcarbapenems. Antimicrobial Agents and Chemotherapy. 1999. vol. 43, No. 3, pp. 460-464.
Air E.L., et al.(2002) Nature Med. 8:179-183.
Andrade-Gordon P. et al. (1999) Proc. Natl. Acad. Sci. U.S. 96:12257-12262.
Dedonder, R.A., et al. (1977) Appl. Environ. Mirobiol. 33: 989-993.
Fotsch, C., et al. (2003) Bioorganic & Medicinal Chemistry Letters 13: 2337-40.
Gadek, T.R., et al. (2002) Science 295: 1086-9.
Greene, J.R., et al. (1982) J. Virol. 41: 715-20.
Greene, J.R., et al. (1984) Proc. Natl. Acad. Sci. USA 81: 7031-5.
Hendrickson W.A., et al. (1997) In Methods in Enzymology. 276: 494-522.
Pedulla M.L., et al. (2003) Corrected Sequence of the Bacteriophage P22 Genome. 185: 1475-77.
Ireton, K., et al. (1993) Genes & Dev. 7: 283-94.
Kim, L., et al. (1996) Gene 181: 71-6.
Kobayashi, K., et al. (2003) Proc. Natl. Acad. Sci. USA 100: 4678-83.
Legrain, P. (2002) Nature Biotechnology 20: 128-9.
Malys, N., et al. (2002) J. Mol. Biol. 319: 289-04.
Martin L., et al. (2003) Nature Biotech. 21:71-76.
Miyazaki K., et al. (2000) J. Mol. Biol. 297:1015-1026.
Noirot-Gros, M.F., et al. (2002) Proc. Natl. Acad. Sci. U.S.A. 99: 8342-8347.
Ohkanda, J., et al. (2001) Bioorganic & Medicinal Chemistry Letters 11: 761-764.
Okubo, S., et al. (1972) Biken J. 15: 81-97.
Salvemini D., et al. (1999) Science 286:304-306.
Salvemini, D., et al. (2002) Nature Reviews 1: 367-74.
Sayers, J.R. (1996) Meth. Enz. 275: 227-38.
Scarlato, V., and S. Gargano (1992) Gene 118: 109-113.
Scott, J.K. (2001) in “Phage Display” C.F. Barbas, et al. (eds.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 4.1-4.13.
Shamoo, Y., (1995) Nature 376: 362-6.
Shamoo Y., et. al. (1997) Nat. Struc. Biol. 4:215-222.
Shamoo, Y., and T.A. Steitz. (1999) Cell 99: 155-166.
Barrett, J.F. et al., Antibacterial agents that inhibit two-component signal transduction systems, Proc. Natl. Acad. Sci. USA, Apr. 1998, pp. 5317-5322, vol. 95.
Biswas, B. et al., Bacteriophage Therapy Rescues Mice Bacteremic from a Clinical Isolate of Vancomycin-Resistant Enterococcus Faecium, Infection and Immunity, Jan. 2002, pp. 204-210, vol. 70(1).
Breithaupt, H., The new antibiotics—Can novel antibacterial treatments combat the rising tide of drug-resistant infections?, Nature Biotechnology, Dec. 1999, pp. 1165-1169, vol. 17.
Drews, J., Drug Discovery: A Historical Perspective, Science, Mar. 2000, pp. 1960-1964, vol. 287.
Dixon, B., Genomics and Innovation in Antibiotics, ASM News, 2002, pp. 106-107, vol. 68.
Einarson, M. et al., Identification of Protein-Protein Interactions with Glutathione-S-Transferase Fusion Proteins, Cold Spring Harbor Laboratory Press, 2001, pp. 37, 57.
Erdmann, J., Bacteria Resistant to Drugs Draw Scrutiny of Biofirms, Genetic Engineering News, May 1999, pp. 1, 19, 50, 58; vol. 19(10).
Glaser, V., Rational Drug Design Plays Big Part in Drug Discovery, Genetic Engineering News, Nov. 1, 1998, pp. 1, 8.
Golemis, E., Protein-Protein Interactions—A Molecular Cloning Manual, Cold Spring Harbor Laboratory Press, 2002, 2 pp.
Harwood, C. et al., Molecular Biological Methods for Bacillus, 1990, 2 pp., John Wiley & Sons Ltd, West Sussex, England.
Johnson, C. et al., Novel antimicrobial targets from combined pahtogen and host genetics, PNAS, Feb. 2000, pp. 958-959, vol. 97(3).
Miller, J., A Short Course in Bacterial Genetics, Cold Spring Harbor Laboratory Press, 1992, 2 pp.
Persidis, A., Antibacterial and antifungal drug discovery, Nature Biotechnology, Nov. 1999, pp. 1141-1142, vol. 17.
Sampath, A. et al., Genetic Analysis of Host-takeover in SPO1 infection ofB. subtilis, Abstracts of the Fourteenth Evergreen International Phage Biology Meeting, Aug. 2001, Poster Section, p. 9.
Sampath, A. et al., Role of SPO1 Genes 44, 50, and 51 in Host-takeover and Bacterial Cell Death, Abstracts of the Fourteenth Evergreen International Phage Biology Meeting, Aug. 2001, p. 5.
Shamoo, Y. et al., Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75 A resolution, Nature Structural Biology, Mar. 1997, pp. 215-222, vol. 4(3).
Zhang, H. et al., New Perspectives on Anti-HER2/Neu Therapeutics, Drug News Perspect, pp. 325-329, vol. 13(6), Aug. 2000.
Spee J.H., et al. (1993) Nucleic Acids Res. 21:777-778.
Smith, R.A., et al. (2001) Bioorganic and Medical Chemistry Letters 11: 2951-4.
Stewart, C.R. (1993) inBacillus subtilisand other gram-positive bacteria (A. Sonenshein, J.A. Hoch, and R. Losick, eds. American Society for Microbiology) pp. 813-829.
Stewart C.R., et al.(1998) Virology 246:329-340.
Stewart C.R. (1999) SPO1 Phage (Myoviridae), in Encyclopedia of Virology (2nd Edition, Webster, R.G., and Granoff, A., eds.) pp. 1681-1685.
Stewart, C.R. et al. (Aug. 8-13, 2001) In Abstracts of the Fourteenth Evergreen International Phage Biology Meeting.
Tatusova, T.A. & T.L. Madden (1999) FEMS Microbiol. Lett. 174: 247-50.
Tian S.S., et al. (1998) Science 281:257-259.
Vandeyar, M.A., and S. A. Zahler (1986) J. Bacteriol. 167: 530-4.
Wanner, B.L. (1986) J. Mol. Biol. 191: 39-58.
Wei P. & Stewart C.R. (1993) A cytotoxic early gene ofBacillus subtilisbacteriophage SPO1. J Bacteriol. 175(24):7887-900.
Wei P. & Stewart C.R. (1995) Genes that protect against the host-killing activity of the E3 protein ofBacillus subtilisbacteriophage SPO1, J. Bacteriol. 177, 2933-2937.
Willats, W.G.T. (2002) Plant Molecular Biology 50: 837-54.
Wrighton, N., and D. Gearing (1999) Nature Biotech. 17: 1157-8.
Duckworth, D. et all, “Bacteriophages: potential treatment for bacterial infections”, BioDrugs 2002;16(1):57-62.
Cudic, M. et al., “Intracellular targets of antibacterial peptides”, Curr Drug Targets Apr. 2002;3(2):101-6.
Sadler, K. et al., “Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7”, Biochemistry Dec. 3, 2002;41(48):14150-7.
Kutter E., “Phage Therapy: Bacteriophages as Antiobiotics” http://www.evergreen.edu/phage/phagetherapy.html, p. 1-24, Nov. 1997.

Affiliated with

Also associated with

Rating

Antimicrobial proteins from the SPO1 bacteriophage does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antimicrobial proteins from the SPO1 bacteriophage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antimicrobial proteins from the SPO1 bacteriophage will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3820194